Mar. 11 at 1:09 PM
BTIG⬆️the PT on
$RAPP to
$53 from
$47 and reiterated at a Buy rating.
$XENE $PRAX $BHVN $JAZZ CNTA ALKS UCBJY
BTIG said in its note—Rapport remains on track to initiate its Phase 3 FOS program in 2Q26 and continues advancing multiple indication expansion opportunities (PGTCS and bipolar mania) and lifecycle management (RAP-219 LAI) opportunities.
Based on RAP-219's open-label Phase 2a FOS data — which showed RAP-219 reduced long episodes by 71% and clinical seizures by 78% — we see a potential best-in-disease profile for RAP-219 as an adjunctive therapy... We have added PGTC seizures into our RAP-219 market forecast based on mechanistic validation and de-risking Ph2a. Co ended 4Q25 with
$490.5M in cash and equiv, funding operations into 2H29.
